Asset
Modzatinib
Aclaris Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06585202 | phase2 | completed | 2024-08-19 | 2025-03-13 | Aclaris Therapeutics, Inc. | Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis |
FDA applications (0)
This company has no applications containing this asset.